Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years
Develop a program to identify, treat, and prevent severe atrophic gastritis to reduce gastric cancer incidence and mortality. In total, 2,847 people aged > 40 years old underwent serological noninvasive screening for atrophic gastritis by identifying postprandial gastrin-17 and pepsinogen-1 in th...
Gespeichert in:
| Veröffentlicht in: | Asian Pacific Journal of Cancer Prevention 2020-02, Vol.21 (2), p.331-336 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 336 |
|---|---|
| container_issue | 2 |
| container_start_page | 331 |
| container_title | Asian Pacific Journal of Cancer Prevention |
| container_volume | 21 |
| creator | Kotelevets, Sergey M Chekh, Sergey A |
| description | Develop a program to identify, treat, and prevent severe atrophic gastritis to reduce gastric cancer incidence and mortality.
In total, 2,847 people aged > 40 years old underwent serological noninvasive screening for atrophic gastritis by identifying postprandial gastrin-17 and pepsinogen-1 in the fasting state. Anti-H pylori IgG was found in 2,134 patients. Seven years later, 2,220 patientswho had undergone serological noninvasive screening were asked to fill out a questionnaire survey (were interviewed). We could not find any information on 627 of 2,847 patients. Next, 75 patients with multifocal atrophic gastritis who underwent gastroscopy and biopsies (the Updated Sydney System (USS)) were selected. To study gastrin-17 production, morpho-functional correlation was studies in 75 patients with multifocal atrophic gastritis.
During seven years, no reported case of gastric cancer was done among 2,220 persons who underwent serological screening and treatment. In the same population, 4.3 persons who did not receive screening during the same period, developed gastric cancer and died of it. In this study, we can say that 4.3 lives were saved out of 2,220 tested persons. The cost for screening this number of people amounted to €23,750. A comparison of the prevalence rate of the four stages of multifocal atrophic gastritis based on the data of the histopathology tests and noninvasive serologic screening in accordance with OLGA classification showed a strong correlation (the correlation coefficient is 0.812). This finding suggested that using this classification not only for histopathology tests for atrophic gastritis but also for serologic markers of antral mucosa and corpus ventriculi atrophy: gastrin-17 and pepsinogen-1.
Complex pathogenetic treatment of atrophic gastritis significantly reduced gastric cancer risk and incidence for such patients.
. |
| doi_str_mv | 10.31557/APJCP.2020.21.2.331 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7332137</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32102507</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3231-db98b5ea65f092c22b7ea292222c12940d4d18028e04b234311431d718c6ec623</originalsourceid><addsrcrecordid>eNpVUWFrGzEMNaNjSbP9gzH8A5qbLd-dL18KIbRpS8cCaaH7ZHw-XeOS2IftBPrv56Vb6ARCD6T3hPQI-cpZIXhVye_z1d1iVQADVgAvoBCCfyBjKGU9lTU8nb3DI3Ie4wtjZdXI6hMZCeAMKibHZFibgOise76gP7yzyYcj1q6jDwF12qFL1Pd0FdBoZzD4faTzFPywsYYudUzBJhupdTRtMI_5OKBJ9oB0nfbdK-19oGs8oKO_UIf4mXzs9Tbil791Qh6vrx4WN9P7n8vbxfx-agQIPu3aWdNWqOuqZzMwAK1EDTPIYTjMStaVHW8YNMjKFkQpOM_ZSd6YGk0NYkIu33SHfbvDzuQzgt6qIdidDq_Ka6v-7zi7Uc_-oKTI3xEyC5RvAiafFAP2Jy5n6uiAOjqg_jiggCtQ2YFM-_Z-74n07-XiN4K5hAw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Kotelevets, Sergey M ; Chekh, Sergey A</creator><creatorcontrib>Kotelevets, Sergey M ; Chekh, Sergey A</creatorcontrib><description>Develop a program to identify, treat, and prevent severe atrophic gastritis to reduce gastric cancer incidence and mortality.
In total, 2,847 people aged > 40 years old underwent serological noninvasive screening for atrophic gastritis by identifying postprandial gastrin-17 and pepsinogen-1 in the fasting state. Anti-H pylori IgG was found in 2,134 patients. Seven years later, 2,220 patientswho had undergone serological noninvasive screening were asked to fill out a questionnaire survey (were interviewed). We could not find any information on 627 of 2,847 patients. Next, 75 patients with multifocal atrophic gastritis who underwent gastroscopy and biopsies (the Updated Sydney System (USS)) were selected. To study gastrin-17 production, morpho-functional correlation was studies in 75 patients with multifocal atrophic gastritis.
During seven years, no reported case of gastric cancer was done among 2,220 persons who underwent serological screening and treatment. In the same population, 4.3 persons who did not receive screening during the same period, developed gastric cancer and died of it. In this study, we can say that 4.3 lives were saved out of 2,220 tested persons. The cost for screening this number of people amounted to €23,750. A comparison of the prevalence rate of the four stages of multifocal atrophic gastritis based on the data of the histopathology tests and noninvasive serologic screening in accordance with OLGA classification showed a strong correlation (the correlation coefficient is 0.812). This finding suggested that using this classification not only for histopathology tests for atrophic gastritis but also for serologic markers of antral mucosa and corpus ventriculi atrophy: gastrin-17 and pepsinogen-1.
Complex pathogenetic treatment of atrophic gastritis significantly reduced gastric cancer risk and incidence for such patients.
.</description><identifier>ISSN: 2476-762X</identifier><identifier>ISSN: 1513-7368</identifier><identifier>EISSN: 2476-762X</identifier><identifier>DOI: 10.31557/APJCP.2020.21.2.331</identifier><identifier>PMID: 32102507</identifier><language>eng</language><publisher>Thailand: West Asia Organization for Cancer Prevention</publisher><subject>Adult ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers - metabolism ; Case-Control Studies ; Female ; Follow-Up Studies ; Gastric Mucosa - drug effects ; Gastric Mucosa - metabolism ; Gastric Mucosa - pathology ; Gastrins - metabolism ; Gastritis, Atrophic - drug therapy ; Gastritis, Atrophic - metabolism ; Gastritis, Atrophic - pathology ; Gastroscopy ; Helicobacter Infections - virology ; Helicobacter pylori - isolation & purification ; Humans ; Male ; Mass Screening - methods ; Pepsinogen A - metabolism ; Precancerous Conditions - drug therapy ; Precancerous Conditions - metabolism ; Precancerous Conditions - pathology ; Prognosis ; Prospective Studies ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - metabolism ; Stomach Neoplasms - pathology</subject><ispartof>Asian Pacific Journal of Cancer Prevention, 2020-02, Vol.21 (2), p.331-336</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3231-db98b5ea65f092c22b7ea292222c12940d4d18028e04b234311431d718c6ec623</citedby><orcidid>0000-0003-2586-3542 ; 0000-0002-9212-5198</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332137/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332137/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32102507$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kotelevets, Sergey M</creatorcontrib><creatorcontrib>Chekh, Sergey A</creatorcontrib><title>Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years</title><title>Asian Pacific Journal of Cancer Prevention</title><addtitle>Asian Pac J Cancer Prev</addtitle><description>Develop a program to identify, treat, and prevent severe atrophic gastritis to reduce gastric cancer incidence and mortality.
In total, 2,847 people aged > 40 years old underwent serological noninvasive screening for atrophic gastritis by identifying postprandial gastrin-17 and pepsinogen-1 in the fasting state. Anti-H pylori IgG was found in 2,134 patients. Seven years later, 2,220 patientswho had undergone serological noninvasive screening were asked to fill out a questionnaire survey (were interviewed). We could not find any information on 627 of 2,847 patients. Next, 75 patients with multifocal atrophic gastritis who underwent gastroscopy and biopsies (the Updated Sydney System (USS)) were selected. To study gastrin-17 production, morpho-functional correlation was studies in 75 patients with multifocal atrophic gastritis.
During seven years, no reported case of gastric cancer was done among 2,220 persons who underwent serological screening and treatment. In the same population, 4.3 persons who did not receive screening during the same period, developed gastric cancer and died of it. In this study, we can say that 4.3 lives were saved out of 2,220 tested persons. The cost for screening this number of people amounted to €23,750. A comparison of the prevalence rate of the four stages of multifocal atrophic gastritis based on the data of the histopathology tests and noninvasive serologic screening in accordance with OLGA classification showed a strong correlation (the correlation coefficient is 0.812). This finding suggested that using this classification not only for histopathology tests for atrophic gastritis but also for serologic markers of antral mucosa and corpus ventriculi atrophy: gastrin-17 and pepsinogen-1.
Complex pathogenetic treatment of atrophic gastritis significantly reduced gastric cancer risk and incidence for such patients.
.</description><subject>Adult</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers - metabolism</subject><subject>Case-Control Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastric Mucosa - drug effects</subject><subject>Gastric Mucosa - metabolism</subject><subject>Gastric Mucosa - pathology</subject><subject>Gastrins - metabolism</subject><subject>Gastritis, Atrophic - drug therapy</subject><subject>Gastritis, Atrophic - metabolism</subject><subject>Gastritis, Atrophic - pathology</subject><subject>Gastroscopy</subject><subject>Helicobacter Infections - virology</subject><subject>Helicobacter pylori - isolation & purification</subject><subject>Humans</subject><subject>Male</subject><subject>Mass Screening - methods</subject><subject>Pepsinogen A - metabolism</subject><subject>Precancerous Conditions - drug therapy</subject><subject>Precancerous Conditions - metabolism</subject><subject>Precancerous Conditions - pathology</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - metabolism</subject><subject>Stomach Neoplasms - pathology</subject><issn>2476-762X</issn><issn>1513-7368</issn><issn>2476-762X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUWFrGzEMNaNjSbP9gzH8A5qbLd-dL18KIbRpS8cCaaH7ZHw-XeOS2IftBPrv56Vb6ARCD6T3hPQI-cpZIXhVye_z1d1iVQADVgAvoBCCfyBjKGU9lTU8nb3DI3Ie4wtjZdXI6hMZCeAMKibHZFibgOise76gP7yzyYcj1q6jDwF12qFL1Pd0FdBoZzD4faTzFPywsYYudUzBJhupdTRtMI_5OKBJ9oB0nfbdK-19oGs8oKO_UIf4mXzs9Tbil791Qh6vrx4WN9P7n8vbxfx-agQIPu3aWdNWqOuqZzMwAK1EDTPIYTjMStaVHW8YNMjKFkQpOM_ZSd6YGk0NYkIu33SHfbvDzuQzgt6qIdidDq_Ka6v-7zi7Uc_-oKTI3xEyC5RvAiafFAP2Jy5n6uiAOjqg_jiggCtQ2YFM-_Z-74n07-XiN4K5hAw</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Kotelevets, Sergey M</creator><creator>Chekh, Sergey A</creator><general>West Asia Organization for Cancer Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2586-3542</orcidid><orcidid>https://orcid.org/0000-0002-9212-5198</orcidid></search><sort><creationdate>20200201</creationdate><title>Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years</title><author>Kotelevets, Sergey M ; Chekh, Sergey A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3231-db98b5ea65f092c22b7ea292222c12940d4d18028e04b234311431d718c6ec623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers - metabolism</topic><topic>Case-Control Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastric Mucosa - drug effects</topic><topic>Gastric Mucosa - metabolism</topic><topic>Gastric Mucosa - pathology</topic><topic>Gastrins - metabolism</topic><topic>Gastritis, Atrophic - drug therapy</topic><topic>Gastritis, Atrophic - metabolism</topic><topic>Gastritis, Atrophic - pathology</topic><topic>Gastroscopy</topic><topic>Helicobacter Infections - virology</topic><topic>Helicobacter pylori - isolation & purification</topic><topic>Humans</topic><topic>Male</topic><topic>Mass Screening - methods</topic><topic>Pepsinogen A - metabolism</topic><topic>Precancerous Conditions - drug therapy</topic><topic>Precancerous Conditions - metabolism</topic><topic>Precancerous Conditions - pathology</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - metabolism</topic><topic>Stomach Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kotelevets, Sergey M</creatorcontrib><creatorcontrib>Chekh, Sergey A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kotelevets, Sergey M</au><au>Chekh, Sergey A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years</atitle><jtitle>Asian Pacific Journal of Cancer Prevention</jtitle><addtitle>Asian Pac J Cancer Prev</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>21</volume><issue>2</issue><spage>331</spage><epage>336</epage><pages>331-336</pages><issn>2476-762X</issn><issn>1513-7368</issn><eissn>2476-762X</eissn><abstract>Develop a program to identify, treat, and prevent severe atrophic gastritis to reduce gastric cancer incidence and mortality.
In total, 2,847 people aged > 40 years old underwent serological noninvasive screening for atrophic gastritis by identifying postprandial gastrin-17 and pepsinogen-1 in the fasting state. Anti-H pylori IgG was found in 2,134 patients. Seven years later, 2,220 patientswho had undergone serological noninvasive screening were asked to fill out a questionnaire survey (were interviewed). We could not find any information on 627 of 2,847 patients. Next, 75 patients with multifocal atrophic gastritis who underwent gastroscopy and biopsies (the Updated Sydney System (USS)) were selected. To study gastrin-17 production, morpho-functional correlation was studies in 75 patients with multifocal atrophic gastritis.
During seven years, no reported case of gastric cancer was done among 2,220 persons who underwent serological screening and treatment. In the same population, 4.3 persons who did not receive screening during the same period, developed gastric cancer and died of it. In this study, we can say that 4.3 lives were saved out of 2,220 tested persons. The cost for screening this number of people amounted to €23,750. A comparison of the prevalence rate of the four stages of multifocal atrophic gastritis based on the data of the histopathology tests and noninvasive serologic screening in accordance with OLGA classification showed a strong correlation (the correlation coefficient is 0.812). This finding suggested that using this classification not only for histopathology tests for atrophic gastritis but also for serologic markers of antral mucosa and corpus ventriculi atrophy: gastrin-17 and pepsinogen-1.
Complex pathogenetic treatment of atrophic gastritis significantly reduced gastric cancer risk and incidence for such patients.
.</abstract><cop>Thailand</cop><pub>West Asia Organization for Cancer Prevention</pub><pmid>32102507</pmid><doi>10.31557/APJCP.2020.21.2.331</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2586-3542</orcidid><orcidid>https://orcid.org/0000-0002-9212-5198</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2476-762X |
| ispartof | Asian Pacific Journal of Cancer Prevention, 2020-02, Vol.21 (2), p.331-336 |
| issn | 2476-762X 1513-7368 2476-762X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7332137 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free E- Journals |
| subjects | Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers - metabolism Case-Control Studies Female Follow-Up Studies Gastric Mucosa - drug effects Gastric Mucosa - metabolism Gastric Mucosa - pathology Gastrins - metabolism Gastritis, Atrophic - drug therapy Gastritis, Atrophic - metabolism Gastritis, Atrophic - pathology Gastroscopy Helicobacter Infections - virology Helicobacter pylori - isolation & purification Humans Male Mass Screening - methods Pepsinogen A - metabolism Precancerous Conditions - drug therapy Precancerous Conditions - metabolism Precancerous Conditions - pathology Prognosis Prospective Studies Stomach Neoplasms - drug therapy Stomach Neoplasms - metabolism Stomach Neoplasms - pathology |
| title | Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T22%3A55%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Screening,%20Monitoring,%20and%20Treatment%20of%20Precancerous%20Atrophic%20Gastritis%20in%20the%20Prospective%20Study%20for%20Seven%20Years&rft.jtitle=Asian%20Pacific%20Journal%20of%20Cancer%20Prevention&rft.au=Kotelevets,%20Sergey%20M&rft.date=2020-02-01&rft.volume=21&rft.issue=2&rft.spage=331&rft.epage=336&rft.pages=331-336&rft.issn=2476-762X&rft.eissn=2476-762X&rft_id=info:doi/10.31557/APJCP.2020.21.2.331&rft_dat=%3Cpubmed_cross%3E32102507%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32102507&rfr_iscdi=true |